Explore / Clinical trial
Clinical trial

Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality

Peking University First HospitalCompletedPhase 4Started May 22, 2023180 enrolledChinaNCT05732064

Abstract

Breast cancer patients often have sleep disturbances during the perioperative period. Dexmedetomidine is a highly selective alpha 2-adrenoceptor agonist with sedative, anxiolytic, and analgesic effects. Previous studies showed that night-time low-dose dexmedetomidine infusion improved sleep quality. Esketamine is a N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and analgesic. Recent studies showed that low-dose esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that low-dose dexmedetomidine-esketamine combined nasal administration at night can improve perioperative sleep quality in patients scheduled for breast cancer surgery.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetaminePalliative care

Keywords

Breast CancerPerioperative periodDexmedetomidineEsketamineSleep qualityBreast CancerPerioperative PeriodDexmedetomidineEsketamineSleep Quality

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.